Skip to main content

Advertisement

SpringerLink
Log in

RETRACTED ARTICLE: Effect of miR-451 on the Biological Behavior of the Esophageal Carcinoma Cell Line EC9706

  • Original Article
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

This article was retracted on 19 October 2019

This article has been updated

Abstract

Background

MicroRNAs play important roles in coordinating a variety of cellular processes. Abnormal expression of miRNAs has been linked to several cancers. However, the functional role of miR-451 in esophageal squamous cell carcinoma remains unclear.

Aims

The present study explored the effects of miR-451 on the biological behavior of the esophageal carcinoma cell line EC9706.

Methods

Synthetic miR-451 mimics were transfected into EC9706 cells using Lipofectamine™ 2000. The expression of miR-451 was analyzed by RT–PCR and the expressions of Bcl-2, AKT and phosphorylated AKT were analyzed by Western blotting. The MTT assay, soft agar colony formation assay, transwell assay and FACS were used to assess the effect of miR-451 on EC9706 cell proliferation, invasion, metastasis and apoptosis. Tumor growth was assessed by subcutaneous inoculation of cells into BALB/c nude mice.

Results

In comparison to the controls, a significant increase in the expression of miR-451 was associated with significantly decreased expressions of Bcl-2, AKT and p-AKT, and a significant increase in the apoptosis rate. The number of cell clones was significantly decreased by miR-451 expression, which also caused the inhibition of cell proliferation. The average number of cells penetrating the matrigel was significantly lower than the controls. Injection of miR-451 inhibited tumor growth in a xenograft model.

Conclusions

Upregulated expression of miR-451 induced apoptosis and suppressed cell proliferation, invasion and metastasis in the esophageal carcinoma cell line EC9706. In addition, injection of miR-451 inhibited tumor growth in a xenograft model of esophageal cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8

Similar content being viewed by others

Change history

  • 19 October 2019

    The Editor-in-Chief has retracted this article [1] because Figure 8 overlaps with Figure 6b of [2] and Figure 6 overlaps with Figure 3 of [3] and Figure 3 of [4].

  • 19 October 2019

    The Editor-in-Chief has retracted this article [1] because Figure��8 overlaps with Figure��6b of [2] and Figure��6 overlaps with Figure��3 of [3] and Figure��3 of [4].

References

  1. Zamore PD, Haley B. Ribo-gnome: the big world of small RNAs. Science. 2005;309:1519–1524.

    Article  CAS  Google Scholar 

  2. Esteller M. Non coding RNAs in human disease. Nat Rev Genet. 2011;12:861–887.

    Article  CAS  Google Scholar 

  3. Van Kouwenhove M, Kedde M, Agami R. MicroRNA regulation by RNA binding proteins and its implications for cancer. Nat Rev Cancer. 2011;11:644–656.

    Article  Google Scholar 

  4. Kozomara A, Griffiths Jones S. miRBase: integrating microRNA annotation and deep sequencing data. Nucleic Acids Res. 2011;39:D152–D157.

    Article  CAS  Google Scholar 

  5. Tie J, Fan D. Big roles of microRNAs in tumorigenesis and tumor development. Histol Histopathol. 2011;26:1353–1361.

    CAS  PubMed  Google Scholar 

  6. Cao XF, Li SQ. Role of miRNA in the diagnosis, prognosis and treatment of esophageal cancer. Zhonghua Zhong Liu Za Zhi. 2011;33:161–164.

    CAS  PubMed  Google Scholar 

  7. Altuvia Y, Landgraf P, Lithwick G, et al. Clustering and conservation patterns of human microRNAs. Nucleic Acids Res. 2005;33:2697–2706.

    Article  CAS  Google Scholar 

  8. Dela Cruz F, Matushansky I. MicroRNAs in chromosomal translocation associated solid tumors: learning from sarcomas. Discov Med. 2011;12:307–317.

    PubMed  Google Scholar 

  9. Negrini M, Ferracin M, Sabbioni S, et al. MicroRNAs in human cancer: from research to therapy. J Cell Sci. 2007;120:1833–1840.

    Article  CAS  Google Scholar 

  10. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006;6:857–866.

    Article  CAS  Google Scholar 

  11. Markou A, Tsaroucha EG, Kaklamanis L, et al. Prognostic value of mature mi-croRNA-21 and microRNA-205 overexpression in non-small cell lung cancer by quantitative real-time RT–PCR. Clin Chem. 2008;54:1696–1704.

    Article  CAS  Google Scholar 

  12. Hu X, Macdonald DM, Huettner PC, et al. A miR-200 microRNA cluster as prognostic marker in advanced ovarian cancer. Gynecol Oncol. 2009;114:457–464.

    Article  CAS  Google Scholar 

  13. Ueda T, Volinia S, Okumura H, et al. Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis. Lancet Oncol. 2010;11:136–146.

    Article  CAS  Google Scholar 

  14. Liu R, Zhang C, Hu Z, et al. A five-microRNA signature identified from genome-wide serum microRNA expression profiling serves as a fingerprint for gastric cancer diagnosis. Eur J Cancer. 2011;47:784–791.

    Article  CAS  Google Scholar 

  15. Takagi T, Iio A, Nakagawa Y, et al. Decreased expression of microRNA-143 and -145 in human gastric cancers. Oncology. 2009;77:12–21.

    Article  CAS  Google Scholar 

  16. Bandres E, Bitarte N, Arias F, et al. microRNA-451 regulates macrophage migration inhibitory factor production and proliferation of gastrointestinal cancer cells. Clin Cancer Res. 2009;15:2281–2290.

    Article  CAS  Google Scholar 

  17. Bian HB, Pan X, Yang JS, et al. Upregulation of microRNA-451 increases cisplatin sensitivity of non-small cell lung cancer cell line (A549). J Exp Clin Cancer Res. 2011;30:20–30.

    Article  CAS  Google Scholar 

  18. Heinzelmann J, Henning B, Sanjmyatav J, et al. Specific miRNA signatures are associated with metastasis and poor prognosis in clear cell renal cell carcinoma. World J Urol. 2011;29:367–373.

    Article  CAS  Google Scholar 

  19. Zhu H, Wu H, Liu X, et al. Role of microRNA miR-27a and miR-451 in the regulation of MDR1/P-glycoprotein expression in human cancer cells. Biochem Pharmacol. 2008;76:582–588.

    Article  CAS  Google Scholar 

  20. Tian Y, Nan Y, Han L, et al. MicroRNA miR-451 downregulates the PI3K/AKT pathway through CAB39 in human glioma. Int J Oncol. 2012;40:1105–1112.

    CAS  PubMed  Google Scholar 

  21. Campani D, Esposito I, Boggi U, et al. Bcl-2 expression in pancreas development and pancreatic cancer progression. J Pathol. 2001;194:444–450.

    Article  CAS  Google Scholar 

  22. Martin AP, Park MA, Mitchell C, et al. BCL-2 family inhibitors enhance histone deacetylase inhibitor and sorafenib lethality via autophagy and overcome blockade of the extrinsic pathway to facilitate killing. Mol Pharmacol. 2009;76:327–341.

    Article  CAS  Google Scholar 

  23. Azmi AS, Wang Z, Philip PA, et al. Emerging Bcl-2 inhibitors for the treatment of cancer. Expert Opin Emerg Drugs. 2010;16:59–70.

    Article  Google Scholar 

  24. Azmi AS, Mohammad RM. Non-peptidic small molecule inhibitors against Bcl-2 for cancer therapy. J Cell Physiol. 2009;218:13–21.

    Article  CAS  Google Scholar 

  25. Regula KM, Ens K, Kirshenbaum LA. IKK beta is required for Bcl-2-mediated NF-kappa B activation in ventricular myocytes. J Biol Chem. 2002;277:38676–38682.

    Article  CAS  Google Scholar 

  26. Mortenson MM, Galante JG, Gilad O, et al. BCL-2 functions as an activator of the AKT signaling pathway in pancreatic cancer. J Cell Biochem. 2007;102:1171–1179.

    Article  CAS  Google Scholar 

  27. Fahy BN, Schlieman MG, Mortenson MM, et al. Targeting BCL-2 overexpression in various human malignancies through NF-kappaB inhibition by the proteasome inhibitor bortezomib. Cancer Chemother Pharmacol. 2005;56:46–54.

    Article  CAS  Google Scholar 

  28. Kumar P, Ning Y, Polverini PJ. Endothelial cells expressing Bcl-2 promotes tumor metastasis by enhancing tumor angiogenesis, blood vessel leakiness and tumor invasion. Lab Invest. 2008;88:740–749.

    Article  CAS  Google Scholar 

  29. Azmi AS, Philip PA, Zafar SF, et al. PAR-4 as a possible new target for pancreatic cancer therapy. Expert Opin Ther Targets. 2010;14:611–620.

    Article  CAS  Google Scholar 

  30. Yang ZZ, Tschopp O, Baudry A, et al. Physiological functions of protein kinase B/Akt. Biochem Soc Trans. 2004;32:350–354.

    Article  CAS  Google Scholar 

  31. Song G, Ouyang G, Bao S. The activation of Akt/PKB signaling pathway and cell survival. J Cell Mol Med. 2005;9:59–71.

    Article  CAS  Google Scholar 

  32. Chen JY, Lin JR, Cimprich KA, Meyer T. A two-dimensional ERK-AKT signaling code for an NGF-triggered cell-fate decision. Mol Cell. 2012;45:196–209.

    Article  CAS  Google Scholar 

  33. Boehme KA, Kulikov R, Blattner C. p53 stabilization in response to DNA damage requires Akt/PKB and DNA–PK. Proc Nat Acad Sci USA. 2008;105:7785–7790.

    Article  CAS  Google Scholar 

Download references

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Department of Tumor, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, People’s Republic of China

    Tao Wang & Yu-ling Zheng

  2. Department of Hemato-Tumor, The First Affiliated Hospital of Henan University of TCM, Zhengzhou, 450000, People’s Republic of China

    Tao Wang

  3. Department of Microbiology and Immunology, College of Basic Medical Sciences, Zhengzhou University, Zhengzhou, 450001, People’s Republic of China

    Wen-qiao Zang, Min Li, Na Wang & Guo-qiang Zhao

Authors
  1. Tao Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wen-qiao Zang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Min Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Na Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yu-ling Zheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Guo-qiang Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Yu-ling Zheng or Guo-qiang Zhao.

Additional information

Co-corresponding author: Yu-ling Zheng

The Editor-in-Chief has retracted this article [1] because Figure 8 overlaps with Figure 6b of [2] and Figure 6 overlaps with Figure 3 of [3] and Figure 3 of [4]. An investigation by Zhengzhou University has confirmed that these figures overlap. The data reported in this article are therefore unreliable. Guo-qiang Zhao does not agree with this retraction. The other authors have not responded to any correspondence about this retraction.

[1] Wang, T., Zang, W., Li, M. et al. Dig Dis Sci (2013) 58: 706. https://doi.org/10.1007/s10620-012-2395-x

[2] Zang, W., Wang, Y., Wang, T. et al. Mol Cancer (2015) 14: 37. https://doi.org/10.1186/s12943-015-0315-3

[3] Yang, Q., Li, M., Wang, T. et al. Diagn Pathol (2013) 8: 132. https://doi.org/10.1186/1746-1596-8-132

[4] Wang, M., Wang, Y., Zang, W. et al. Tumor Biol. (2014) 35: 39. https://doi.org/10.1007/s13277-013-1004-8

About this article

Cite this article

Wang, T., Zang, Wq., Li, M. et al. RETRACTED ARTICLE: Effect of miR-451 on the Biological Behavior of the Esophageal Carcinoma Cell Line EC9706. Dig Dis Sci 58, 706–714 (2013). https://doi.org/10.1007/s10620-012-2395-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-012-2395-x

Keywords

Search

Navigation